{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:22:52Z","timestamp":1792603372753,"version":"4.5.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH031"],"award-info":[{"award-number":["ZR2020MH031"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["202201- -065"],"award-info":[{"award-number":["202201- -065"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02891-7","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:03:23Z","timestamp":1779437003000},"page":"2167-2189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 receptor agonists in metabolic dysfunction\u2013associated steatotic liver disease: mechanistic networks and translational implications: a review"],"prefix":"10.1007","volume":"49","author":[{"given":"Xuejia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2891_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78:1966\u20131986. https:\/\/doi.org\/10.1097\/hep.0000000000000520","journal-title":"Hepatology"},{"key":"2891_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK (2024) Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol 12:1433857. https:\/\/doi.org\/10.3389\/fcell.2024.1433857","journal-title":"Front Cell Dev Biol"},{"key":"2891_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton S, Freitas P, Hjelmes\u00e6th J, Kabisch M, Kandler K, Lingvay I et al (2025) Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 13:949\u2013963. https:\/\/doi.org\/10.1016\/s2213-8587(25)00226-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2891_CR5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"2891_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000539371","volume":"17","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2024) EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts 17:374\u2013444. https:\/\/doi.org\/10.1159\/000539371","journal-title":"Obes Facts"},{"key":"2891_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","volume":"22","author":"LA Abushamat","year":"2024","unstructured":"Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D (2024) The emerging role of Glucagon-Like Peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol 22:1565\u20131574. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.032","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2891_CR8","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","volume":"31","author":"M Jara","year":"2025","unstructured":"Jara M, Norlin J, Kj\u00e6r MS, Almholt K, Bendtsen KM, Bugianesi E et al (2025) Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med 31:3128\u20133140. https:\/\/doi.org\/10.1038\/s41591-025-03799-0","journal-title":"Nat Med"},{"key":"2891_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119324","author":"HA Lee","year":"2023","unstructured":"Lee HA, Kim HY (2023) Therapeutic mechanisms and clinical effects of Glucagon-like Peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24119324","journal-title":"Int J Mol Sci"},{"key":"2891_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/s2468-1253(22)00317-x","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH et al (2023) Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 8:20\u201330. https:\/\/doi.org\/10.1016\/s2468-1253(22)00317-x","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2891_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","volume":"23","author":"F Magkos","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC et al (2016) Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 23:591\u2013601. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.005","journal-title":"Cell Metab"},{"key":"2891_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05371-4","volume":"7","author":"H Ando","year":"2017","unstructured":"Ando H, Gotoh K, Fujiwara K, Anai M, Chiba S, Masaki T et al (2017) Glucagon-like peptide-1 reduces pancreatic \u03b2-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats. Sci Rep 7:5578. https:\/\/doi.org\/10.1038\/s41598-017-05371-4","journal-title":"Sci Rep"},{"key":"2891_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101352","volume":"54","author":"Y Dong","year":"2021","unstructured":"Dong Y, Carty J, Goldstein N, He Z, Hwang E, Chau D et al (2021) Time and metabolic state-dependent effects of GLP-1R agonists on NPY\/AgRP and POMC neuronal activity in vivo. Mol Metab 54:101352. https:\/\/doi.org\/10.1016\/j.molmet.2021.101352","journal-title":"Mol Metab"},{"key":"2891_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1126\/science.adj2537","volume":"385","author":"KS Kim","year":"2024","unstructured":"Kim KS, Park JS, Hwang E, Park MJ, Shin HY, Lee YH et al (2024) GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science 385:438\u2013446. https:\/\/doi.org\/10.1126\/science.adj2537","journal-title":"Science"},{"key":"2891_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/dmso.S387116","volume":"16","author":"M Aldawsari","year":"2023","unstructured":"Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M (2023) The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: Systematic review of randomized controlled trials. Diabetes Metab Syndr Obes 16:575\u2013595. https:\/\/doi.org\/10.2147\/dmso.S387116","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2891_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cmet.2012.06.015","volume":"16","author":"HJ Grill","year":"2012","unstructured":"Grill HJ, Hayes MR (2012) Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab 16:296\u2013309. https:\/\/doi.org\/10.1016\/j.cmet.2012.06.015","journal-title":"Cell Metab"},{"key":"2891_CR17","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","volume":"69","author":"J Yan","year":"2019","unstructured":"Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T et al (2019) Liraglutide, Sitagliptin, and Insulin Glargine added to Metformin: The effect on body weight and intrahepatic lipid in patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology 69:2414\u20132426. https:\/\/doi.org\/10.1002\/hep.30320","journal-title":"Hepatology"},{"key":"2891_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X et al (2023) The weight-loss effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in non-diabetic individuals with overweight or obesity: A systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr 118:614\u2013626. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.017","journal-title":"Am J Clin Nutr"},{"key":"2891_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40261-024-01354-2","volume":"44","author":"X Tan","year":"2024","unstructured":"Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL et al (2024) Real-world effectiveness of once-weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for glycemic control and weight outcomes in Type 2 Diabetes Mellitus (RELATE). Clin Drug Investig 44:271\u2013284. https:\/\/doi.org\/10.1007\/s40261-024-01354-2","journal-title":"Clin Drug Investig"},{"key":"2891_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S et al (2023) A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 78:471\u2013478. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.010","journal-title":"J Hepatol"},{"key":"2891_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9:234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"2891_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409\u20131439. https:\/\/doi.org\/10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"2891_CR23","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2337\/db12-1013","volume":"62","author":"KA Kaihara","year":"2013","unstructured":"Kaihara KA, Dickson LM, Jacobson DA, Tamarina N, Roe MW, Philipson LH et al (2013) \u03b2-Cell-specific protein kinase a activation enhances the efficiency of glucose control by increasing acute-phase insulin secretion. Diabetes 62:1527\u20131536. https:\/\/doi.org\/10.2337\/db12-1013","journal-title":"Diabetes"},{"key":"2891_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tem.2013.10.004","volume":"25","author":"M Almahariq","year":"2014","unstructured":"Almahariq M, Mei FC, Cheng X (2014) Cyclic AMP sensor EPAC proteins and energy homeostasis. Trends Endocrinol Metab 25:60\u201371. https:\/\/doi.org\/10.1016\/j.tem.2013.10.004","journal-title":"Trends Endocrinol Metab"},{"key":"2891_CR25","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13852","volume":"6","author":"R Ramracheya","year":"2018","unstructured":"Ramracheya R, Chapman C, Chibalina M, Dou H, Miranda C, Gonz\u00e1lez A et al (2018) GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca(2+) channels. Physiol Rep 6:e13852. https:\/\/doi.org\/10.14814\/phy2.13852","journal-title":"Physiol Rep"},{"key":"2891_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1369\/0022155415583535","volume":"63","author":"MF Brereton","year":"2015","unstructured":"Brereton MF, Vergari E, Zhang Q, Clark A (2015) Alpha-, delta- and PP-cells: are they the architectural cornerstones of islet structure and co-ordination? J Histochem Cytochem 63:575\u2013591. https:\/\/doi.org\/10.1369\/0022155415583535","journal-title":"J Histochem Cytochem"},{"key":"2891_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2337\/db08-0792","volume":"58","author":"AC Hauge-Evans","year":"2009","unstructured":"Hauge-Evans AC, King AJ, Carmignac D, Richardson CC, Robinson IC, Low MJ et al (2009) Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 58:403\u2013411. https:\/\/doi.org\/10.2337\/db08-0792","journal-title":"Diabetes"},{"key":"2891_CR28","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.1074\/jbc.M117.786525","volume":"292","author":"JM Irimia","year":"2017","unstructured":"Irimia JM, Meyer CM, Segvich DM, Surendran S, DePaoli-Roach AA, Morral N et al (2017) Lack of liver glycogen causes hepatic insulin resistance and steatosis in mice. J Biol Chem 292:10455\u201310464. https:\/\/doi.org\/10.1074\/jbc.M117.786525","journal-title":"J Biol Chem"},{"key":"2891_CR29","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI (2021) Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184:2537\u20132564. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015","journal-title":"Cell"},{"key":"2891_CR30","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.2337\/db12-0206","volume":"61","author":"C Flannery","year":"2012","unstructured":"Flannery C, Dufour S, Rab\u00f8l R, Shulman GI, Petersen KF (2012) Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 61:2711\u20132717. https:\/\/doi.org\/10.2337\/db12-0206","journal-title":"Diabetes"},{"key":"2891_CR31","doi-asserted-by":"publisher","first-page":"15597","DOI":"10.1073\/pnas.0405238101","volume":"101","author":"S Ishii","year":"2004","unstructured":"Ishii S, Iizuka K, Miller BC, Uyeda K (2004) Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A 101:15597\u201315602. https:\/\/doi.org\/10.1073\/pnas.0405238101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2891_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091691","author":"A Koceva","year":"2025","unstructured":"Koceva A, Jane\u017e A, Jensterle M (2025) Impact of incretin-based therapy on skeletal muscle health. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina61091691","journal-title":"Medicina (Kaunas)"},{"key":"2891_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4093\/dmj.2017.41.5.327","volume":"41","author":"M Periasamy","year":"2017","unstructured":"Periasamy M, Herrera JL, Reis FCG (2017) Skeletal muscle thermogenesis and its role in whole body energy metabolism. Diabetes Metab J 41:327\u2013336. https:\/\/doi.org\/10.4093\/dmj.2017.41.5.327","journal-title":"Diabetes Metab J"},{"key":"2891_CR34","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/nutrit\/nuac006","volume":"80","author":"F Magkos","year":"2022","unstructured":"Magkos F (2022) Is calorie restriction beneficial for normal-weight individuals? A narrative review of the effects of weight loss in the presence and absence of obesity. Nutr Rev 80:1811\u20131825. https:\/\/doi.org\/10.1093\/nutrit\/nuac006","journal-title":"Nutr Rev"},{"key":"2891_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s2468-1253(22)00338-7","volume":"8","author":"G Targher","year":"2023","unstructured":"Targher G, Mantovani A, Byrne CD (2023) Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 8:179\u2013191. https:\/\/doi.org\/10.1016\/s2468-1253(22)00338-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2891_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.777026","volume":"9","author":"H Li","year":"2021","unstructured":"Li H, Donelan W, Wang F, Zhang P, Yang L, Ding Y et al (2021) GLP-1 induces the expression of FNDC5 derivatives that execute lipolytic actions. Front Cell Dev Biol 9:777026. https:\/\/doi.org\/10.3389\/fcell.2021.777026","journal-title":"Front Cell Dev Biol"},{"key":"2891_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","volume":"44","author":"JM Yabut","year":"2023","unstructured":"Yabut JM, Drucker DJ (2023) Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev 44:14\u201332. https:\/\/doi.org\/10.1210\/endrev\/bnac018","journal-title":"Endocr Rev"},{"key":"2891_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2337\/db12-0202","volume":"62","author":"GJ Hein","year":"2013","unstructured":"Hein GJ, Baker C, Hsieh J, Farr S, Adeli K (2013) GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 62:373\u2013381. https:\/\/doi.org\/10.2337\/db12-0202","journal-title":"Diabetes"},{"key":"2891_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101590","volume":"65","author":"S Hoffman","year":"2022","unstructured":"Hoffman S, Alvares D, Adeli K (2022) GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. Mol Metab 65:101590. https:\/\/doi.org\/10.1016\/j.molmet.2022.101590","journal-title":"Mol Metab"},{"key":"2891_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dom.13487","volume":"21","author":"N Matikainen","year":"2019","unstructured":"Matikainen N, S\u00f6derlund S, Bj\u00f6rnson E, Pietil\u00e4inen K, Hakkarainen A, Lundbom N et al (2019) Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab 21:84\u201394. https:\/\/doi.org\/10.1111\/dom.13487","journal-title":"Diabetes Obes Metab"},{"key":"2891_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli A, Cusi K (2019) From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep 1:312\u2013328. https:\/\/doi.org\/10.1016\/j.jhepr.2019.07.002","journal-title":"JHEP Rep"},{"key":"2891_CR42","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","volume":"55","author":"YS Lee","year":"2012","unstructured":"Lee YS, Park MS, Choung JS, Kim SS, Oh HH, Choi CS et al (2012) Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55:2456\u20132468. https:\/\/doi.org\/10.1007\/s00125-012-2592-3","journal-title":"Diabetologia"},{"key":"2891_CR43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL et al (2016) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64:399\u2013408. https:\/\/doi.org\/10.1016\/j.jhep.2015.08.038","journal-title":"J Hepatol"},{"key":"2891_CR44","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1111\/bcp.14855","volume":"87","author":"LE Simental-Mend\u00eda","year":"2021","unstructured":"Simental-Mend\u00eda LE, S\u00e1nchez-Garc\u00eda A, Linden-Torres E, Simental-Mend\u00eda M (2021) Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 87:4140\u20134149. https:\/\/doi.org\/10.1111\/bcp.14855","journal-title":"Br J Clin Pharmacol"},{"key":"2891_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1530\/joe-18-0374","volume":"240","author":"L Zhao","year":"2019","unstructured":"Zhao L, Zhu C, Lu M, Chen C, Nie X, Abudukerimu B et al (2019) The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution. J Endocrinol 240:271\u2013286. https:\/\/doi.org\/10.1530\/joe-18-0374","journal-title":"J Endocrinol"},{"key":"2891_CR46","doi-asserted-by":"publisher","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","volume":"302","author":"JL Trevaskis","year":"2012","unstructured":"Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS et al (2012) Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302:G762-772. https:\/\/doi.org\/10.1152\/ajpgi.00476.2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2891_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13574","volume":"24","author":"I Akoumianakis","year":"2023","unstructured":"Akoumianakis I, Zagaliotis A, Konstantaraki M, Filippatos TD (2023) GLP-1 analogs and regional adiposity: a systematic review and meta-analysis. Obes Rev 24:e13574. https:\/\/doi.org\/10.1111\/obr.13574","journal-title":"Obes Rev"},{"key":"2891_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108592","volume":"24","author":"T Hropot","year":"2023","unstructured":"Hropot T, Herman R, Janez A, Lezaic L, Jensterle M (2023) Brown adipose tissue: a new potential target for glucagon-like peptide 1 receptor agonists in the treatment of obesity. Int J Mol Sci 24:108592. https:\/\/doi.org\/10.3390\/ijms24108592","journal-title":"Int J Mol Sci"},{"key":"2891_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1667037","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, Chu H, Yang L (2025) White adipose tissue browning and peroxisome proliferator activated receptors in MASLD. Front Endocrinol (Lausanne) 16:1667037. https:\/\/doi.org\/10.3389\/fendo.2025.1667037","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2891_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12020-024-03734-2","volume":"85","author":"L Zhao","year":"2024","unstructured":"Zhao L, Li W, Zhang P, Wang D, Yang L, Yuan G (2024) Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice. Endocrine 85:222\u2013232. https:\/\/doi.org\/10.1007\/s12020-024-03734-2","journal-title":"Endocrine"},{"key":"2891_CR51","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392:2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"2891_CR52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N et al (2023) Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8:511\u2013522. https:\/\/doi.org\/10.1016\/s2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2891_CR53","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M et al (2021) Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 54:1150\u20131161. https:\/\/doi.org\/10.1111\/apt.16608","journal-title":"Aliment Pharmacol Ther"},{"key":"2891_CR54","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63:2434\u20132445. https:\/\/doi.org\/10.1007\/s00125-020-05265-7","journal-title":"Diabetologia"},{"key":"2891_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3292","volume":"36","author":"L Liu","year":"2020","unstructured":"Liu L, Yan H, Xia M, Zhao L, Lv M, Zhao N et al (2020) Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 36:e3292. https:\/\/doi.org\/10.1002\/dmrr.3292","journal-title":"Diabetes Metab Res Rev"},{"key":"2891_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02439-x","volume":"23","author":"L Meng","year":"2025","unstructured":"Meng L, Lu F, Zhang B, Ma Y, Gao J (2025) Taming fatty liver: can taurine combat metabolic dysfunction in MASLD? Cell Commun Signal 23:439. https:\/\/doi.org\/10.1186\/s12964-025-02439-x","journal-title":"Cell Commun Signal"},{"key":"2891_CR57","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/liv.12120","volume":"33","author":"L Zhang","year":"2013","unstructured":"Zhang L, Yang M, Ren H, Hu H, Boden G, Li L et al (2013) GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int 33:794\u2013804. https:\/\/doi.org\/10.1111\/liv.12120","journal-title":"Liver Int"},{"key":"2891_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.21006","volume":"43","author":"X Ding","year":"2006","unstructured":"Ding X, Saxena NK, Lin S, Gupta NA, Anania FA (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology 43:173\u2013181. https:\/\/doi.org\/10.1002\/hep.21006","journal-title":"Hepatology"},{"key":"2891_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.970292","volume":"13","author":"C Fang","year":"2022","unstructured":"Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J et al (2022) The AMPK pathway in fatty liver disease. Front Physiol 13:970292. https:\/\/doi.org\/10.3389\/fphys.2022.970292","journal-title":"Front Physiol"},{"key":"2891_CR60","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s00125-011-2317-z","volume":"54","author":"SL Samson","year":"2011","unstructured":"Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R et al (2011) Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 54:3093\u20133100. https:\/\/doi.org\/10.1007\/s00125-011-2317-z","journal-title":"Diabetologia"},{"key":"2891_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-020-01286-8","volume":"19","author":"K Kolczynska","year":"2020","unstructured":"Kolczynska K, Loza-Valdes A, Hawro I, Sumara G (2020) Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review. Lipids Health Dis 19:113. https:\/\/doi.org\/10.1186\/s12944-020-01286-8","journal-title":"Lipids Health Dis"},{"key":"2891_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020751","author":"W Wan","year":"2023","unstructured":"Wan W, Qin Q, Xie L, Zhang H, Wu F, Stevens RC et al (2023) GLP-1R Signaling and Functional Molecules in Incretin Therapy. Molecules. https:\/\/doi.org\/10.3390\/molecules28020751","journal-title":"Molecules"},{"key":"2891_CR63","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK et al (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51:1584\u20131592. https:\/\/doi.org\/10.1002\/hep.23569","journal-title":"Hepatology"},{"key":"2891_CR64","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/d41591-023-00055-1","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho T (2023) Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH. Nat Med 29:1881. https:\/\/doi.org\/10.1038\/d41591-023-00055-1","journal-title":"Nat Med"},{"key":"2891_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00672","volume":"9","author":"J Rowlands","year":"2018","unstructured":"Rowlands J, Heng J, Newsholme P, Carlessi R (2018) Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol (Lausanne) 9:672. https:\/\/doi.org\/10.3389\/fendo.2018.00672","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2891_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44080239","volume":"44","author":"T Omanovic Kolaric","year":"2022","unstructured":"Omanovic Kolaric T, Kizivat T, Mihaljevic V, Zjalic M, Bilic-Curcic I, Kuna L et al (2022) Liraglutide exerts protective effects by downregulation of PPAR\u03b3, ACSL1 and SREBP-1c in Huh7 cell culture models of non-alcoholic steatosis and drug-induced steatosis. Curr Issues Mol Biol 44:3465-3480. https:\/\/doi.org\/10.3390\/cimb44080239","journal-title":"Curr Issues Mol Biol"},{"key":"2891_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2021.170597","volume":"143","author":"L Jin","year":"2021","unstructured":"Jin L, Sun Y, Li Y, Zhang H, Yu W, Li Y et al (2021) A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis. Peptides 143:170597. https:\/\/doi.org\/10.1016\/j.peptides.2021.170597","journal-title":"Peptides"},{"key":"2891_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.602574","volume":"8","author":"Y Fang","year":"2020","unstructured":"Fang Y, Ji L, Zhu C, Xiao Y, Zhang J, Lu J et al (2020) Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway. Front Cell Dev Biol 8:602574. https:\/\/doi.org\/10.3389\/fcell.2020.602574","journal-title":"Front Cell Dev Biol"},{"key":"2891_CR69","doi-asserted-by":"publisher","first-page":"32443","DOI":"10.1073\/pnas.2011442117","volume":"117","author":"RJ Schulze","year":"2020","unstructured":"Schulze RJ, Krueger EW, Weller SG, Johnson KM, Casey CA, Schott MB et al (2020) Direct lysosome-based autophagy of lipid droplets in hepatocytes. Proc Natl Acad Sci U S A 117:32443\u201332452. https:\/\/doi.org\/10.1073\/pnas.2011442117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2891_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091256","author":"T Kassouf","year":"2020","unstructured":"Kassouf T, Sumara G (2020) Impact of conventional and atypical MAPKs on the development of metabolic diseases. Biomolecules. https:\/\/doi.org\/10.3390\/biom10091256","journal-title":"Biomolecules"},{"key":"2891_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0954-6","volume":"18","author":"YR Wu","year":"2019","unstructured":"Wu YR, Shi XY, Ma CY, Zhang Y, Xu RX, Li JJ (2019) Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway. Cardiovasc Diabetol 18:146. https:\/\/doi.org\/10.1186\/s12933-019-0954-6","journal-title":"Cardiovasc Diabetol"},{"key":"2891_CR72","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.3390\/cimb45060288","volume":"45","author":"A Petrovic","year":"2023","unstructured":"Petrovic A, Igrec D, Rozac K, Bojanic K, Kuna L, Kolaric TO et al (2023) The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD. Curr Issues Mol Biol 45:4544\u20134556. https:\/\/doi.org\/10.3390\/cimb45060288","journal-title":"Curr Issues Mol Biol"},{"key":"2891_CR73","doi-asserted-by":"publisher","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","volume":"302","author":"JE Mells","year":"2012","unstructured":"Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA et al (2012) Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 302:G225-235. https:\/\/doi.org\/10.1152\/ajpgi.00274.2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2891_CR74","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3892\/etm.2015.2741","volume":"10","author":"YG Wang","year":"2015","unstructured":"Wang YG, Yang TL (2015) Liraglutide reduces fatty degeneration in hepatic cells via the AMPK\/SREBP1 pathway. Exp Ther Med 10:1777\u20131783. https:\/\/doi.org\/10.3892\/etm.2015.2741","journal-title":"Exp Ther Med"},{"key":"2891_CR75","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1111\/jgh.70084","volume":"40","author":"L Liu","year":"2025","unstructured":"Liu L, Xia Y, Wang B, Zhang Y (2025) Efficacy of incretin-based therapies in patients with metabolic dysfunction-associated steatotic liver disease: an updated systematic review and meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 40:2659\u20132673. https:\/\/doi.org\/10.1111\/jgh.70084","journal-title":"J Gastroenterol Hepatol"},{"key":"2891_CR76","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F (2022) Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 77:1136\u20131160. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.012","journal-title":"J Hepatol"},{"key":"2891_CR77","doi-asserted-by":"publisher","first-page":"G264","DOI":"10.1152\/ajpgi.00153.2023","volume":"326","author":"S Larion","year":"2024","unstructured":"Larion S, Padgett CA, Mintz JD, Thompson JA, Butcher JT, Belin de Chantem\u00e8le EJ et al (2024) NADPH oxidase 1 promotes hepatic steatosis in obese mice and is abrogated by augmented skeletal muscle mass. Am J Physiol Gastrointest Liver Physiol 326:G264-g273. https:\/\/doi.org\/10.1152\/ajpgi.00153.2023","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2891_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119649","volume":"1871","author":"M Tanaka","year":"2024","unstructured":"Tanaka M, Kaji K, Nishimura N, Asada S, Koizumi A, Matsuda T et al (2024) Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1871:119649. https:\/\/doi.org\/10.1016\/j.bbamcr.2023.119649","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"2891_CR79","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/j.gastro.2015.04.009","volume":"149","author":"A Bettaieb","year":"2015","unstructured":"Bettaieb A, Jiang JX, Sasaki Y, Chao TI, Kiss Z, Chen X et al (2015) Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice. Gastroenterology 149:468-480.e410. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.009","journal-title":"Gastroenterology"},{"key":"2891_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14010083","volume":"14","author":"V Cammisotto","year":"2025","unstructured":"Cammisotto V, Valeriani E, Pignatelli P, Violi F (2025) Nicotinamide adenine dinucleotide phosphate oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease. Antioxidants (Basel) 14:0083. https:\/\/doi.org\/10.3390\/antiox14010083","journal-title":"Antioxidants (Basel)"},{"key":"2891_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154320","author":"N Perakakis","year":"2020","unstructured":"Perakakis N, Stefanakis K, Mantzoros CS (2020) The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism. https:\/\/doi.org\/10.1016\/j.metabol.2020.154320","journal-title":"Metabolism"},{"key":"2891_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10020174","volume":"10","author":"JC Arroyave-Ospina","year":"2021","unstructured":"Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H (2021) Role of oxidative stress in the pathogenesis of Non-Alcoholic Fatty Liver Disease: implications for prevention and therapy. Antioxidants (Basel) 10:0174. https:\/\/doi.org\/10.3390\/antiox10020174","journal-title":"Antioxidants (Basel)"},{"key":"2891_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9060687","volume":"9","author":"D Gabbia","year":"2021","unstructured":"Gabbia D, Cannella L, De Martin S (2021) The role of oxidative stress in NAFLD-NASH-HCC transition-focus on NADPH oxidases. Biomedicines 9:0687. https:\/\/doi.org\/10.3390\/biomedicines9060687","journal-title":"Biomedicines"},{"key":"2891_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143435","volume":"20","author":"YC Wu","year":"2019","unstructured":"Wu YC, Wang WT, Lee SS, Kuo YR, Wang YC, Yen SJ et al (2019) Glucagon-like peptide-1 receptor agonist attenuates autophagy to ameliorate Pulmonary Arterial Hypertension through Drp1\/NOX- and Atg-5\/Atg-7\/Beclin-1\/LC3\u03b2 pathways. Int J Mol Sci 20:3435. https:\/\/doi.org\/10.3390\/ijms20143435","journal-title":"Int J Mol Sci"},{"key":"2891_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113222","volume":"142","author":"R Lv","year":"2024","unstructured":"Lv R, Zhao Y, Wang X, He Y, Dong N, Min X et al (2024) GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2\/HO-1 and MAPK\/NF-\u03baB signaling pathways. Int Immunopharmacol 142:113222. https:\/\/doi.org\/10.1016\/j.intimp.2024.113222","journal-title":"Int Immunopharmacol"},{"key":"2891_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/toxics13070594","volume":"13","author":"EA Elsiad","year":"2025","unstructured":"Elsiad EA, Abd El Aal HA, Salem HA, El-Yamany MF, Rabie MA (2025) Liraglutide attenuates Atorvastatin-induced hepatotoxicity by restoring GLP-1R expression and activating Nrf2 and autophagy pathways in Wistar rats. Toxics 13:0594. https:\/\/doi.org\/10.3390\/toxics13070594","journal-title":"Toxics"},{"key":"2891_CR87","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1080\/21655979.2022.2036902","volume":"13","author":"J Ji","year":"2022","unstructured":"Ji J, Feng M, Huang Y, Niu X (2022) Liraglutide inhibits receptor for advanced glycation end products (RAGE)\/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. Bioengineered 13:5091\u20135102. https:\/\/doi.org\/10.1080\/21655979.2022.2036902","journal-title":"Bioengineered"},{"key":"2891_CR88","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/a-1240-4936","volume":"129","author":"T Fang","year":"2021","unstructured":"Fang T, Huang S, Chen Y, Chen Z, Chen J, Hu W (2021) Glucagon like peptide-1 receptor agonists alter pancreatic and hepatic histology and regulation of endoplasmic reticulum stress in high-fat diet mouse model. Exp Clin Endocrinol Diabetes 129:625\u2013633. https:\/\/doi.org\/10.1055\/a-1240-4936","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2891_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025269","volume":"6","author":"S Sharma","year":"2011","unstructured":"Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA (2011) GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE 6:e25269. https:\/\/doi.org\/10.1371\/journal.pone.0025269","journal-title":"PLoS ONE"},{"key":"2891_CR90","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6237405","volume":"2022","author":"MW Kong","year":"2022","unstructured":"Kong MW, Gao Y, Xie YY, Xing EH, Sun LX, Ma HJ et al (2022) Mechanism of GLP-1 receptor agonists-mediated attenuation of palmitic acid-induced lipotoxicity in L6 myoblasts. BioMed Res Int 2022:6237405. https:\/\/doi.org\/10.1155\/2022\/6237405","journal-title":"BioMed Res Int"},{"key":"2891_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1675552","volume":"16","author":"B Gong","year":"2025","unstructured":"Gong B, Li C, Shi Z, Wang F, Dai R, Chen G et al (2025) GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy. Front Pharmacol 16:1675552. https:\/\/doi.org\/10.3389\/fphar.2025.1675552","journal-title":"Front Pharmacol"},{"key":"2891_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262010234","author":"V Elian","year":"2025","unstructured":"Elian V, Popovici V, Steriade AT, Radulian G, Ozon EA, Moro\u0219an E et al (2025) Molecular biomarkers and therapeutic approach of patients with diabetes and obstructive sleep apnea. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms262010234","journal-title":"Int J Mol Sci"},{"key":"2891_CR93","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","volume":"103","author":"I Ros-Madrid","year":"2025","unstructured":"Ros-Madrid I, Cano-M\u00e1rmol R, Ferrer-Gomez M, Ramos-Molina B (2025) Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. Can J Physiol Pharmacol 103:369\u2013377. https:\/\/doi.org\/10.1139\/cjpp-2025-0148","journal-title":"Can J Physiol Pharmacol"},{"key":"2891_CR94","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/jdi.12063","volume":"4","author":"L He","year":"2013","unstructured":"He L, Wong CK, Cheung KK, Yau HC, Fu A, Zhao HL et al (2013) Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J Diabetes Investig 4:382\u2013392. https:\/\/doi.org\/10.1111\/jdi.12063","journal-title":"J Diabetes Investig"},{"key":"2891_CR95","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1074\/jbc.M116.714873","volume":"291","author":"B Yun","year":"2016","unstructured":"Yun B, Lee H, Jayaraja S, Suram S, Murphy RC, Leslie CC (2016) Prostaglandins from Cytosolic Phospholipase A2\u03b1\/Cyclooxygenase-1 pathway and Mitogen-activated Protein Kinases regulate gene expression in Candida albicans-infected macrophages. J Biol Chem 291:7070\u20137086. https:\/\/doi.org\/10.1074\/jbc.M116.714873","journal-title":"J Biol Chem"},{"key":"2891_CR96","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/jcb.24425","volume":"114","author":"SY Chang","year":"2013","unstructured":"Chang SY, Kim DB, Ryu GR, Ko SH, Jeong IK, Ahn YB et al (2013) Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP\/PKA pathway. J Cell Biochem 114:844\u2013853. https:\/\/doi.org\/10.1002\/jcb.24425","journal-title":"J Cell Biochem"},{"key":"2891_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-019-0218-y","volume":"16","author":"Q Que","year":"2019","unstructured":"Que Q, Guo X, Zhan L, Chen S, Zhang Z, Ni X et al (2019) The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis. J Inflamm 16:13. https:\/\/doi.org\/10.1186\/s12950-019-0218-y","journal-title":"J Inflamm"},{"key":"2891_CR98","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/376509","volume":"2011","author":"B Portha","year":"2011","unstructured":"Portha B, Tourrel-Cuzin C, Movassat J (2011) Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res 2011:376509. https:\/\/doi.org\/10.1155\/2011\/376509","journal-title":"Exp Diabetes Res"},{"key":"2891_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2023.114348","volume":"363","author":"H Yi","year":"2023","unstructured":"Yi H, Duan Y, Song R, Zhou Y, Cui Y, Liu C et al (2023) Activation of glucagon-like peptide-1 receptor in microglia exerts protective effects against sepsis-induced encephalopathy via attenuating endoplasmic reticulum stress-associated inflammation and apoptosis in a mouse model of sepsis. Exp Neurol 363:114348. https:\/\/doi.org\/10.1016\/j.expneurol.2023.114348","journal-title":"Exp Neurol"},{"key":"2891_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152822","volume":"789","author":"MA Ngabea","year":"2025","unstructured":"Ngabea MA, Dimeji IY (2025) GLP-1 receptor agonists and inflammatory pathway modulation: dual targeting of metabolic and immune dysfunction in insulin resistance. Biochem Biophys Res Commun 789:152822. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152822","journal-title":"Biochem Biophys Res Commun"},{"key":"2891_CR101","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20165826","volume":"49","author":"C Guo","year":"2016","unstructured":"Guo C, Huang T, Chen A, Chen X, Wang L, Shen F et al (2016) Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. Braz J Med Biol Res 49:e5826. https:\/\/doi.org\/10.1590\/1414-431x20165826","journal-title":"Braz J Med Biol Res"},{"key":"2891_CR102","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/jpp\/rgad014","volume":"75","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang X, Zhang S, Wang J, Wang M, Ma T et al (2023) Wei-Tong-Xin exerts anti-inflammatory effects through TLR4-mediated macrophages M1\/M2 polarization and affects GLP-1 secretion. J Pharm Pharmacol 75:574\u2013584. https:\/\/doi.org\/10.1093\/jpp\/rgad014","journal-title":"J Pharm Pharmacol"},{"key":"2891_CR103","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1007\/s00018-015-1995-y","volume":"72","author":"A Sica","year":"2015","unstructured":"Sica A, Erreni M, Allavena P, Porta C (2015) Macrophage polarization in pathology. Cell Mol Life Sci 72:4111\u20134126. https:\/\/doi.org\/10.1007\/s00018-015-1995-y","journal-title":"Cell Mol Life Sci"},{"key":"2891_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100018","volume":"77","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lau HC, Yu J (2025) Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: current and emerging therapeutic options. Pharmacol Rev 77:100018. https:\/\/doi.org\/10.1016\/j.pharmr.2024.100018","journal-title":"Pharmacol Rev"},{"key":"2891_CR105","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jot.2022.02.001","volume":"32","author":"C Meurot","year":"2022","unstructured":"Meurot C, Jacques C, Martin C, Sudre L, Breton J, Rattenbach R et al (2022) Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: a new opportunity? J Orthop Transl 32:121\u2013129. https:\/\/doi.org\/10.1016\/j.jot.2022.02.001","journal-title":"J Orthop Transl"},{"key":"2891_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-022-00574-6","volume":"28","author":"Q Xu","year":"2022","unstructured":"Xu Q, Zhang X, Li T, Shao S (2022) Exenatide regulates Th17\/Treg balance via PI3K\/Akt\/FoxO1 pathway in db\/db mice. Mol Med 28:144. https:\/\/doi.org\/10.1186\/s10020-022-00574-6","journal-title":"Mol Med"},{"key":"2891_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163288","volume":"14","author":"A Mazzieri","year":"2023","unstructured":"Mazzieri A, Basta G, Calafiore R, Luca G (2023) GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway. Front Immunol 14:1163288. https:\/\/doi.org\/10.3389\/fimmu.2023.1163288","journal-title":"Front Immunol"},{"key":"2891_CR108","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","volume":"36","author":"CK Wong","year":"2024","unstructured":"Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N et al (2024) Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab 36:130-143.e135. https:\/\/doi.org\/10.1016\/j.cmet.2023.11.009","journal-title":"Cell Metab"},{"key":"2891_CR109","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri.2017.11","volume":"17","author":"O Krenkel","year":"2017","unstructured":"Krenkel O, Tacke F (2017) Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 17:306\u2013321. https:\/\/doi.org\/10.1038\/nri.2017.11","journal-title":"Nat Rev Immunol"},{"key":"2891_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172715","volume":"864","author":"X Yu","year":"2019","unstructured":"Yu X, Hao M, Liu Y, Ma X, Lin W, Xu Q et al (2019) Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol 864:172715. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172715","journal-title":"Eur J Pharmacol"},{"key":"2891_CR111","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/15548627.2023.2254191","volume":"20","author":"Q Ren","year":"2024","unstructured":"Ren Q, Sun Q, Fu J (2024) Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease. Autophagy 20:221\u2013241. https:\/\/doi.org\/10.1080\/15548627.2023.2254191","journal-title":"Autophagy"},{"key":"2891_CR112","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/hepr.12634","volume":"46","author":"W Tong","year":"2016","unstructured":"Tong W, Ju L, Qiu M, Xie Q, Chen Y, Shen W et al (2016) Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1\/SIRT3-FOXO3a pathway. Hepatol Res 46:933\u2013943. https:\/\/doi.org\/10.1111\/hepr.12634","journal-title":"Hepatol Res"},{"key":"2891_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031394","volume":"7","author":"J Lee","year":"2012","unstructured":"Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC et al (2012) Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice. PLoS ONE 7:e31394. https:\/\/doi.org\/10.1371\/journal.pone.0031394","journal-title":"PLoS ONE"},{"key":"2891_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2025.106987","volume":"178","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Wang J, Hu X, Lu W, Cao Y, Niu C et al (2025) GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK\/SIRT1 pathway to improve NAFLD. Prostaglandins Other Lipid Mediat 178:106987. https:\/\/doi.org\/10.1016\/j.prostaglandins.2025.106987","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2891_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.630962","volume":"8","author":"M Yao","year":"2021","unstructured":"Yao M, Zhang J, Li Z, Bai X, Ma J, Li Y (2021) Liraglutide protects nucleus pulposus cells against high-glucose induced apoptosis by activating PI3K\/Akt\/ mTOR\/Caspase-3 and PI3K\/Akt\/GSK3\u03b2\/Caspase-3 signaling pathways. Front Med (Lausanne) 8:630962. https:\/\/doi.org\/10.3389\/fmed.2021.630962","journal-title":"Front Med (Lausanne)"},{"key":"2891_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175730","volume":"949","author":"Y Wang","year":"2023","unstructured":"Wang Y, Deng F, Zhong X, Du Y, Fan X, Su H et al (2023) Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis. Eur J Pharmacol 949:175730. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175730","journal-title":"Eur J Pharmacol"},{"key":"2891_CR117","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.metabol.2014.04.011","volume":"63","author":"J Lee","year":"2014","unstructured":"Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW et al (2014) Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis. Metabolism 63:1041\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2014.04.011","journal-title":"Metabolism"},{"key":"2891_CR118","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ebiom.2019.02.037","volume":"41","author":"J Liu","year":"2019","unstructured":"Liu J, Yang K, Yang J, Xiao W, Le Y, Yu F et al (2019) Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. EBioMedicine 41:73\u201384. https:\/\/doi.org\/10.1016\/j.ebiom.2019.02.037","journal-title":"EBioMedicine"},{"key":"2891_CR119","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","volume":"37","author":"JP Rose","year":"2025","unstructured":"Rose JP, Morgan DA, Sullivan AI, Fu X, Inigo-Vollmer M, Burgess SC et al (2025) FGF21 reverses MASH through coordinated actions on the CNS and liver. Cell Metab 37:1515-1529.e1516. https:\/\/doi.org\/10.1016\/j.cmet.2025.04.014","journal-title":"Cell Metab"},{"key":"2891_CR120","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/hep.31856","volume":"74","author":"D Liu","year":"2021","unstructured":"Liu D, Pang J, Shao W, Gu J, Zeng Y, He HH et al (2021) Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. Hepatology 74:2154\u20132169. https:\/\/doi.org\/10.1002\/hep.31856","journal-title":"Hepatology"},{"key":"2891_CR121","doi-asserted-by":"publisher","first-page":"22063","DOI":"10.1038\/s41598-021-01663-y","volume":"11","author":"S Ghosal","year":"2021","unstructured":"Ghosal S, Datta D, Sinha B (2021) A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep 11:22063. https:\/\/doi.org\/10.1038\/s41598-021-01663-y","journal-title":"Sci Rep"},{"key":"2891_CR122","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fendo.2017.00008","volume":"8","author":"G Heinrich","year":"2017","unstructured":"Heinrich G, Ghadieh HE, Ghanem SS, Muturi HT, Rezaei K, Al-Share QY et al (2017) Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 8:8. https:\/\/doi.org\/10.3389\/fendo.2017.00008","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2891_CR123","doi-asserted-by":"publisher","DOI":"10.29011\/2574.7568.000033","author":"HE Ghadieh","year":"2017","unstructured":"Ghadieh HE, Muturi HT, Najjar SM (2017) Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism. J Diabetes Treat. https:\/\/doi.org\/10.29011\/2574.7568.000033","journal-title":"J Diabetes Treat"},{"key":"2891_CR124","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/hep4.1117","volume":"2","author":"HE Ghadieh","year":"2018","unstructured":"Ghadieh HE, Muturi HT, Russo L, Marino CC, Ghanem SS, Khuder SS et al (2018) Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis. Hepatol Commun 2:35\u201347. https:\/\/doi.org\/10.1002\/hep4.1117","journal-title":"Hepatol Commun"},{"key":"2891_CR125","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke F, Puengel T, Loomba R, Friedman SL (2023) An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol 79:552\u2013566. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.038","journal-title":"J Hepatol"},{"key":"2891_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093746","volume":"9","author":"LS Jun","year":"2014","unstructured":"Jun LS, Showalter AD, Ali N, Dai F, Ma W, Coskun T et al (2014) A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor. PLoS ONE 9:e93746. https:\/\/doi.org\/10.1371\/journal.pone.0093746","journal-title":"PLoS ONE"},{"key":"2891_CR127","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-017-02866-y","volume":"7","author":"FC de Mesquita","year":"2017","unstructured":"de Mesquita FC, Guix\u00e9-Muntet S, Fern\u00e1ndez-Iglesias A, Maeso-D\u00edaz R, Vila S, Hide D et al (2017) Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. Sci Rep 7:3255. https:\/\/doi.org\/10.1038\/s41598-017-02866-y","journal-title":"Sci Rep"},{"key":"2891_CR128","doi-asserted-by":"publisher","first-page":"13360","DOI":"10.1038\/s41598-025-97872-w","volume":"15","author":"B Fan","year":"2025","unstructured":"Fan B, Meng L, Zheng X, Bai L, Du Y, Ding H et al (2025) Liraglutide inhibits the proliferation of rat hepatic stellate cells under high glucose conditions by suppressing the ERK signaling pathway. Sci Rep 15:13360. https:\/\/doi.org\/10.1038\/s41598-025-97872-w","journal-title":"Sci Rep"},{"key":"2891_CR129","doi-asserted-by":"publisher","first-page":"19087","DOI":"10.4238\/2015.December.29.17","volume":"14","author":"LK Wu","year":"2015","unstructured":"Wu LK, Liu YC, Shi LL, Lu KD (2015) Glucagon-like peptide-1 receptor agonists inhibit hepatic stellate cell activation by blocking the p38 MAPK signaling pathway. Genet Mol Res 14:19087\u201319093. https:\/\/doi.org\/10.4238\/2015.December.29.17","journal-title":"Genet Mol Res"},{"key":"2891_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411606","author":"O Khalifa","year":"2023","unstructured":"Khalifa O, Ouararhni K, Errafii K, Alajez NM, Arredouani A (2023) Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241411606","journal-title":"Int J Mol Sci"},{"key":"2891_CR131","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00210-025-04675-x","volume":"399","author":"OA Hawary","year":"2026","unstructured":"Hawary OA, Wadie W, El-Said YAM, Hassan OF (2026) Repurposing of semaglutide by targeting SIRT1 and TGF-\u03b2\/Smad signaling in hepatic fibrosis. Naunyn Schmiedebergs Arch Pharmacol 399:4413\u20134425. https:\/\/doi.org\/10.1007\/s00210-025-04675-x","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2891_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177106","volume":"985","author":"YC Liu","year":"2024","unstructured":"Liu YC, Tseng YH, Wu YH, Tong L, Tsai SP, Huang SE et al (2024) Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway. Eur J Pharmacol 985:177106. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177106","journal-title":"Eur J Pharmacol"},{"key":"2891_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194651","author":"K Arvanitakis","year":"2022","unstructured":"Arvanitakis K, Koufakis T, Kotsa K, Germanidis G (2022) How far beyond diabetes can the benefits of glucagon-like peptide-1 receptor agonists go? A review of the evidence on their effects on hepatocellular carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14194651","journal-title":"Cancers (Basel)"},{"key":"2891_CR134","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/onc.2017.38","volume":"36","author":"M Zhou","year":"2017","unstructured":"Zhou M, Mok MT, Sun H, Chan AW, Huang Y, Cheng AS et al (2017) The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. Oncogene 36:4135\u20134149. https:\/\/doi.org\/10.1038\/onc.2017.38","journal-title":"Oncogene"},{"key":"2891_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165722","author":"M Kojima","year":"2020","unstructured":"Kojima M, Takahashi H, Kuwashiro T, Tanaka K, Mori H, Ozaki I et al (2020) Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21165722","journal-title":"Int J Mol Sci"},{"key":"2891_CR136","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70256","volume":"45","author":"A Mantovani","year":"2025","unstructured":"Mantovani A, Morandin R, Fiorio V, Lando MG, Stefan N, Tilg H et al (2025) Glucagon-like peptide-1 receptor agonists improve MASH and liver fibrosis: A meta-analysis of randomised controlled trials. Liver Int 45:e70256. https:\/\/doi.org\/10.1111\/liv.70256","journal-title":"Liver Int"},{"key":"2891_CR137","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jgh.16752","volume":"40","author":"PRC Passos","year":"2025","unstructured":"Passos PRC, Filho VOC, Noronha MM, Hyppolito EB, Saldanha EF, Motta RV (2025) Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis. J Gastroenterol Hepatol 40:67\u201377. https:\/\/doi.org\/10.1111\/jgh.16752","journal-title":"J Gastroenterol Hepatol"},{"key":"2891_CR138","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.3748\/wjg.v30.i43.4682","volume":"30","author":"M Guney-Coskun","year":"2024","unstructured":"Guney-Coskun M, Basaranoglu M (2024) Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World J Gastroenterol 30:4682\u20134688. https:\/\/doi.org\/10.3748\/wjg.v30.i43.4682","journal-title":"World J Gastroenterol"},{"key":"2891_CR139","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/mog.0000000000000349","volume":"33","author":"K Brandl","year":"2017","unstructured":"Brandl K, Schnabl B (2017) Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol 33:128\u2013133. https:\/\/doi.org\/10.1097\/mog.0000000000000349","journal-title":"Curr Opin Gastroenterol"},{"key":"2891_CR140","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.celrep.2017.10.008","volume":"21","author":"LJ Lebrun","year":"2017","unstructured":"Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros JP, Le Guern N, Plesnik J et al (2017) Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Rep 21:1160\u20131168. https:\/\/doi.org\/10.1016\/j.celrep.2017.10.008","journal-title":"Cell Rep"},{"key":"2891_CR141","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3748\/wjg.v30.i23.2964","volume":"30","author":"J Rocho\u0144","year":"2024","unstructured":"Rocho\u0144 J, Kalinowski P, Szymanek-Majchrzak K, Gr\u0105t M (2024) Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 30:2964\u20132980. https:\/\/doi.org\/10.3748\/wjg.v30.i23.2964","journal-title":"World J Gastroenterol"},{"key":"2891_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/nu17081303","author":"KK Gofron","year":"2025","unstructured":"Gofron KK, Wasilewski A, Ma\u0142gorzewicz S (2025) Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review. Nutrients. https:\/\/doi.org\/10.3390\/nu17081303","journal-title":"Nutrients"},{"key":"2891_CR143","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2147\/dmso.S451129","volume":"17","author":"C Xiong","year":"2024","unstructured":"Xiong C, Wu J, Ma Y, Li N, Wang X, Li Y et al (2024) Effects of glucagon-like peptide-1 receptor agonists on gut microbiota in Dehydroepiandrosterone-induced Polycystic Ovary Syndrome mice: Compared evaluation of liraglutide and semaglutide intervention. Diabetes Metab Syndr Obes 17:865\u2013880. https:\/\/doi.org\/10.2147\/dmso.S451129","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2891_CR144","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.17891","volume":"12","author":"J Feng","year":"2024","unstructured":"Feng J, Teng Z, Yang Y, Liu J, Chen S (2024) Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice. PeerJ 12:e17891. https:\/\/doi.org\/10.7717\/peerj.17891","journal-title":"PeerJ"},{"key":"2891_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1048693","volume":"9","author":"L Zhao","year":"2022","unstructured":"Zhao L, Qiu Y, Zhang P, Wu X, Zhao Z, Deng X et al (2022) Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet. Front Nutr 9:1048693. https:\/\/doi.org\/10.3389\/fnut.2022.1048693","journal-title":"Front Nutr"},{"key":"2891_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52103-x","volume":"9","author":"MSA Madsen","year":"2019","unstructured":"Madsen MSA, Holm JB, Pallej\u00e0 A, Wismann P, Fabricius K, Rigbolt K et al (2019) Metabolic and gut microbiome changes following GLP-1 or dual GLP-1\/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep 9:15582. https:\/\/doi.org\/10.1038\/s41598-019-52103-x","journal-title":"Sci Rep"},{"key":"2891_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2021.101223","volume":"47","author":"MM Smits","year":"2021","unstructured":"Smits MM, Fluitman KS, Herrema H, Davids M, Kramer MHH, Groen AK et al (2021) Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. Diabetes Metab 47:101223. https:\/\/doi.org\/10.1016\/j.diabet.2021.101223","journal-title":"Diabetes Metab"},{"key":"2891_CR148","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10123-023-00380-y","volume":"27","author":"X Niu","year":"2024","unstructured":"Niu X, Lu P, Huang L, Sun Y, Jin M, Liu J et al (2024) The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes. Int Microbiol 27:265\u2013276. https:\/\/doi.org\/10.1007\/s10123-023-00380-y","journal-title":"Int Microbiol"},{"key":"2891_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109784","volume":"27","author":"L Liang","year":"2024","unstructured":"Liang L, Su X, Guan Y, Wu B, Zhang X, Nian X (2024) Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment-a preliminary longitudinal study. iScience 27:109784. https:\/\/doi.org\/10.1016\/j.isci.2024.109784","journal-title":"iScience"},{"key":"2891_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040383","author":"JE Hunt","year":"2021","unstructured":"Hunt JE, Holst JJ, Jeppesen PB, Kissow H (2021) GLP-1 and intestinal diseases. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9040383","journal-title":"Biomedicines"},{"key":"2891_CR151","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/jgh.13808","volume":"33","author":"T Nozu","year":"2018","unstructured":"Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T (2018) Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats. J Gastroenterol Hepatol 33:232\u2013239. https:\/\/doi.org\/10.1111\/jgh.13808","journal-title":"J Gastroenterol Hepatol"},{"key":"2891_CR152","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02032-23","volume":"15","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Wu Y, Zhang Q, Xiao X (2024) Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. MBio 15:e0203223. https:\/\/doi.org\/10.1128\/mbio.02032-23","journal-title":"MBio"},{"key":"2891_CR153","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2947549","volume":"2020","author":"N Zhang","year":"2020","unstructured":"Zhang N, Tao J, Gao L, Bi Y, Li P, Wang H et al (2020) Liraglutide attenuates nonalcoholic fatty liver disease by modulating gut microbiota in rats administered a high-fat diet. BioMed Res Int 2020:2947549. https:\/\/doi.org\/10.1155\/2020\/2947549","journal-title":"BioMed Res Int"},{"key":"2891_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-024-00610-9","volume":"10","author":"X Sun","year":"2024","unstructured":"Sun X, Shukla M, Wang W, Li S (2024) Unlocking gut-liver-brain axis communication metabolites: energy metabolism, immunity and barriers. npj Biofilms Microbiomes 10:136. https:\/\/doi.org\/10.1038\/s41522-024-00610-9","journal-title":"npj Biofilms Microbiomes"},{"key":"2891_CR155","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"Bajaj HS, Newsome PN, Sanyal AJ, Kliers I, \u00d8Stergaard LH, Long MT, et al (2025) Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatotic liver disease(MASH). Canadian Journal of Diabetes 49:S2-S3.","journal-title":"JAMA Intern Med"},{"key":"2891_CR156","doi-asserted-by":"publisher","DOI":"10.1177\/0004563216648250","volume":"53","author":"J Cegla","year":"2016","unstructured":"Cegla J (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study. Ann Clin Biochem 53:518. https:\/\/doi.org\/10.1177\/0004563216648250","journal-title":"Ann Clin Biochem"},{"key":"2891_CR157","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E et al (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"key":"2891_CR158","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK et al (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 30:2037\u20132048. https:\/\/doi.org\/10.1038\/s41591-024-03018-2","journal-title":"Nat Med"},{"key":"2891_CR159","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s40618-025-02700-7","volume":"48","author":"D Tuccinardi","year":"2025","unstructured":"Tuccinardi D, Masi D, Watanabe M, Zanghi Buffi V, De Domenico F, Berti S et al (2025) Precision obesity medicine: a phenotype-guided framework for pharmacologic therapy across the lifespan. J Endocrinol Invest 48:2761\u20132798. https:\/\/doi.org\/10.1007\/s40618-025-02700-7","journal-title":"J Endocrinol Invest"},{"key":"2891_CR160","first-page":"6","volume":"20","author":"N Alkhouri","year":"2024","unstructured":"Alkhouri N (2024) Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. Gastroenterol Hepatol 20:6\u20137","journal-title":"Gastroenterol Hepatol"},{"key":"2891_CR161","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E et al (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391:311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa2401755","journal-title":"N Engl J Med"},{"key":"2891_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. https:\/\/doi.org\/10.3390\/metabo11020073","journal-title":"Metabolites"},{"key":"2891_CR163","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/s0140-6736(18)32261-x","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr., Granger CB, Jones NP et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519\u20131529. https:\/\/doi.org\/10.1016\/s0140-6736(18)32261-x","journal-title":"Lancet"},{"key":"2891_CR164","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121\u2013130. https:\/\/doi.org\/10.1016\/s0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"2891_CR165","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001706","author":"I Lingvay","year":"2020","unstructured":"Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R et al (2020) Superior weight loss with once-weekly Semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res Care. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001706","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2891_CR166","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","volume":"42","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB (2019) Effects of Liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care 42:1912\u20131920. https:\/\/doi.org\/10.2337\/dc19-0415","journal-title":"Diabetes Care"},{"key":"2891_CR167","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/dom.15524","volume":"26","author":"MF Abdelmalek","year":"2024","unstructured":"Abdelmalek MF, Harrison SA, Sanyal AJ (2024) The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis. Diabetes Obes Metab 26:2001\u20132016. https:\/\/doi.org\/10.1111\/dom.15524","journal-title":"Diabetes Obes Metab"},{"key":"2891_CR168","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","volume":"134","author":"S Wharton","year":"2022","unstructured":"Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM et al (2022) Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med 134:14\u201319. https:\/\/doi.org\/10.1080\/00325481.2021.2002616","journal-title":"Postgrad Med"},{"key":"2891_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102475","volume":"69","author":"SBK Jensen","year":"2024","unstructured":"Jensen SBK, Blond MB, Sandsdal RM, Olsen LM, Juhl CR, Lundgren JR et al (2024) Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 69:102475. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102475","journal-title":"EClinicalMedicine"},{"key":"2891_CR170","doi-asserted-by":"publisher","first-page":"E620","DOI":"10.1152\/ajpendo.00069.2016","volume":"311","author":"T Jin","year":"2016","unstructured":"Jin T, Weng J (2016) Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. Am J Physiol Endocrinol Metab 311:E620-627. https:\/\/doi.org\/10.1152\/ajpendo.00069.2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2891_CR171","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s42000-024-00541-2","volume":"23","author":"C Tsiampali","year":"2024","unstructured":"Tsiampali C, Vachliotis ID, Goulas A, Polyzos SA (2024) Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease. Hormones (Athens) 23:611\u2013619. https:\/\/doi.org\/10.1007\/s42000-024-00541-2","journal-title":"Hormones (Athens)"},{"key":"2891_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47040285","author":"M Al Qassab","year":"2025","unstructured":"Al Qassab M, Mneimneh M, Jradi A, Derbas B, Dabboussi D, Khoury Baini J et al (2025) The expanding role of GLP-1 receptor agonists: advancing clinical outcomes in metabolic and mental health. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47040285","journal-title":"Curr Issues Mol Biol"},{"key":"2891_CR173","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1089\/dna.2020.5424","volume":"39","author":"W Li","year":"2020","unstructured":"Li W, Li P, Li R, Yu Z, Sun X, Ji G et al (2020) GLP1R single-nucleotide polymorphisms rs3765467 and rs10305492 affect \u03b2 cell insulin secretory capacity and apoptosis through GLP-1. DNA Cell Biol 39:1700\u20131710. https:\/\/doi.org\/10.1089\/dna.2020.5424","journal-title":"DNA Cell Biol"},{"key":"2891_CR174","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00228-021-03249-z","volume":"78","author":"Z Guan","year":"2022","unstructured":"Guan Z, Du Y, Li R, Zhang S, Xu Y, Zhang X et al (2022) Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study. Eur J Clin Pharmacol 78:793\u2013799. https:\/\/doi.org\/10.1007\/s00228-021-03249-z","journal-title":"Eur J Clin Pharmacol"},{"key":"2891_CR175","doi-asserted-by":"publisher","DOI":"10.1172\/jci186425","author":"PN Newsome","year":"2025","unstructured":"Newsome PN, Loomba R (2025) Therapeutic horizons in metabolic dysfunction-associated steatohepatitis. J Clin Invest. https:\/\/doi.org\/10.1172\/jci186425","journal-title":"J Clin Invest"},{"key":"2891_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/nu17152409","author":"L Schiavo","year":"2025","unstructured":"Schiavo L, Santella B, Mingo M, Rossetti G, Orio M, Pilone V (2025) Beyond weight loss: comparative effects of tirzepatide plus low-energy ketogenic versus low-calorie diet on hepatic steatosis and stiffness in MASLD. Nutrients. https:\/\/doi.org\/10.3390\/nu17152409","journal-title":"Nutrients"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02891-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:08:50Z","timestamp":1787292530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02891-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":175,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2891"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02891-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}